Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): A double-blind randomised control trial

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Dunn, Liam ^a   Flenady, Vicki ^a   Kumar, Sailesh ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Caesarean section; Fetal distress; Intrapartum fetal compromise; Sildenafil citrate

Indexed keywords

LACTIC ACID; PLACEBO; SILDENAFIL;

ADULT; APGAR SCORE; ARTICLE; BLOOD PH; BRAIN DISEASE; CESAREAN SECTION; CHILDBIRTH; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMERGENCY SURGERY; FEMALE; FETUS DISTRESS; FETUS ECHOGRAPHY; FETUS HEART RATE; GESTATIONAL AGE; HOSPITAL ADMISSION; HUMAN; LABOR; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MECONIUM; NEWBORN DEATH; NEWBORN INTENSIVE CARE; PHASE 2 CLINICAL TRIAL; PLACENTA CIRCULATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; CLINICAL TRIAL; FETAL DISTRESS; PREGNANCY; RISK FACTOR;

DOUBLE-BLIND METHOD; FEMALE; FETAL DISTRESS; HUMANS; PREGNANCY; RISK FACTORS; SILDENAFIL CITRATE;

EID: 84954145647     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0769-0     Document Type: Article

References (45)

1. Janbu T, Nesheim B. Uterine artery blood velocities during contractions in pregnancy and labour related to intrauterine pressure. Br J Obstet Gynaecol. 1987;94(12):1150-5.
2. Low JA, Pickersgill H, Killen H, Derrick E. The prediction and prevention of intrapartum fetal asphyxia in term pregnancies. Am J Obstet Gynecol. 2001;184(4):724-30.
3. McIntyre S, Taitz D, Keogh J, Goldsmith S, Badawi N, Blair E. A systematic review of risk factors for cerebral palsy in children born at term in developed countries. Dev Med Child Neurol. 2013;55(6):499-508.
4. Bhutta ZA, Black R. Global maternal, newborn, and child health-so near and yet so far. N Engl J Med. 2013;369(23):2226-35.
5. Prior T, Mullins E, Bennett P, Kumar S. Prediction of intrapartum fetal compromise using the cerebroumbilical ratio: a prospective observational study. Am J Obstet Gynecol. 2013;208(2):124.e1-6.
6. Prior T, Mullins E, Bennett P, Kumar S. Umbilical venous flow rate in term fetuses: can variations in flow predict intrapartum compromise? Am J Obstet Gynecol. 2014;210(1):61.e1-8.
7. Osol G, Celia G, Gokina N, Barron C, Chien E, Mandala M, Luksha L, Kublickiene K. Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol. 2008;294(3):H1381-7.
8. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba N, Kenny L, Redman C, Shennan A. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121-31.
9. Herraiz I, Droge LA, Gomez-Montes E, Henrich W, Galindo A, Verlohren S. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol. 2014;124(2 Pt 1):265-73.
10. Asvold BO, Vatten LJ, Romundstad PR, Jenum PA, Karumanchi SA, Eskild A. Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. Am J Epidemiol. 2011;173(6):630-9.
11. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006;195(1):40-9.
12. Sher G, Fisch JD. Vaginal sildenafil (Viagra): a preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF. Hum Reprod. 2000;15:806-9.
13. Sher G, Fisch JD. Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development. Fertil Steril. 2002;78:1073-6.
14. Paulus WE, Strehler E, Zhang M, Jelinkova L, El-Danasouri I, Sterzik K. Benefit of vaginal sildenafil citrate in assisted reproduction therapy. Fertil Steril. 2002;77:846-7.
15. Dilworth MR, Andersson I, Renshall LJ, Cowley E, Baker P, Greenwood S, Sibley CP, Wareing M. Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype. PLoS One. 2013;8(10):e77748.
16. Wareing M, Myers JE, O'Hara M, Baker P. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab. 2005;90(5):2550-5.
17. Granger JP, George EM, Dent EA, Palei AC. Sildenafil attenuates placental ischemia-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2013;305(4):R397-403.
18. Herraiz S, Pellicer B, Serra V, Cauli O, Cortijo J, Felip V, Pellicer A. Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats. BJOG. 2012;119(11):1394-402.
19. Stanley JL, Andersson IJ, Poudel R, Rueda-Clausen CF, Sibley CP, Davidge ST, Baker PN. Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension. 2012;59(5):1021-8.
20. Samangaya RA, Wareing M, Skillern L, Baker PN. Phosphodiesterase inhibitor effect on small artery function in preeclampsia. Hypertens Pregnancy. 2011;30(2):144-52.
21. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor Sildenafil for the treatment of preeclampsia. Hypertens Pregnancy. 2009;28(4):369-82.
22. Lin TH, Su YN, Shih JC, Hsu HC, Lee CN. Resolution of high uterine artery pulsatility index and notching following Sildenafil citrate treatment in a growth-restricted pregnancy. Ultrasound Obstet Gynecol. 2012;40(5):609-10.
23. von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, Lim KI, Liston RM, Miller Sp, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG. 2011;118(5):624-8.
24. Ganzevoort W, Alfirevic Z, von Dadelszen P, Kenny L, Papageorghiou A, van Wassenaer-Leemhuis A, Gluud C, Mol BW, Baker PN. STRIDER: sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction-a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014;3:23.
25. th August 2015.
26. Subbaiah M, Kumar S, Roy KK, Sharma JB, Singh N. Pregnancy outcome in women with pulmonary arterial hypertension: single-center experience from India. Arch Gynecol Obstet. 2013;288:305-9.
27. Duarte AG, Thomas S, Safdar Z, Torres F, Pacheco LD, Feldman J, DeBoisblanc B. Management of pulmonary arterial hypertension during pregnancy a retrospective, multicenter experience. Chest. 2013;143(5):1330-6.
28. Goland S, Tsai F, Habib M, Janmohamed M, Goodwin TM, Elkayam U. Favorable outcome of pregnancy with an elective use of epoprostenol and sildenafil in women with severe pulmonary hypertension. Cardiology. 2010;115:205-8.
29. Molelekwa V, Akhter P, McKenna P, Bowen M, Walsh K. Eisenmenger's syndrome in a 27 week pregnancy-management with bosentan and sildenafil. Ir Med J. 2005;98:87-8.
30. Lacassie HJ, Germain AM, Valdes G, Fernandez MS, Allamand F, Lopez H. Management of Eisenmenger syndrome in pregnancy with sildenafil and L arginine. Obstet Gynecol. 2004;103:118-20.
31. Ng WPK, Yip WL. Successful maternal-foetal outcome using nitric oxide and sildenafil in pulmonary hypertension with atrial septal defect and HIV infection. Singap Med J. 2012;53(1):e3-5.
32. Vallaneuva-Garcai D, Mota-Rojas D, Hernandez-Gonzalez R, et al. A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. J Obstet Gynaecol. 2007;27(3):255-9.
33. National Institute for Health and Care Excellence. Intrapartum care for healthy women and babies. Clinical Guideline. Published: 3 December 2014. nice.org.uk/guidance/cg190.
34. Roberts CL, Lancaster PA. Australian national birthweight percentiles by gestational age. Med J Aust. 1999;170(3):114-8.
35. Grace L, Greer R, Kumar S. Perinatal consequences of a category 1 caesarean section at term. BMJ Open. 2015;5:e007248. doi: 10.1136/bmjopen-2014-007248.
36. World Health Organisation. Appropriate technology for birth. Lancet. 1985;2:436-7.
37. Ye J, Betran AP, Vela MG, Souza JP, Zhang J. Searching for the optimal rate of medically necessary cesarean delivery. Birth. 2014;41(3):237-44.
38. Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2006. Natl Vital Stat Rep. 2007;56:1-20.
39. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Fay Menacker PH, Kirmeyer S, Matthews TJ. Births: final data for 2005. Natl Vital Stat Rep. 2006;56:1-18.
40. Robson MA. Can we reduce the caesarean section rate? Best Pract Res Clin Obstet Gynaecol. 2001;15:179-94.
41. Menacker F, Hamilton BE. Recent trends in cesarean delivery in the United States. NCHS Data Brief. 2010;35:1-8.
42. Stavrou EP, Ford JB, Shand AW, Morris JM, Roberts CL. Epidemiology and trends for caesarean section births in New South Wales, Australia: a population-based study. BMC Pregnancy Childbirth. 2011;11:8.
43. Osterman MJ, Martin JA. Changes in caesarean delivery rates by gestational age: United States, 1996-2011. NCHS Data Brief. 2013;124:1-8.
44. Health and Social Care Information Centre. NHS Maternity Statistics-England, April 2012 to March 2013: Provider level analysis. Leeds: HSCIC; 2013. http://www.hscic.gov.uk/catalogue/PUB12744. Accessed 2 Oct 2015.
45. Li Z, Zeki R, Hilder L, Sullivan EA. Australia's mothers and babies 2010. Perinatal statistics series no. 27. Cat. no. PER 57. Canberra: AIHW National Perinatal Epidemiology and Statistics Unit. 2012.